Share This Post

Focus in RCC shifts to new frontline strategies

From OncLive

Three recent drug approvals have shifted the landscape in the second-line setting for renal cell carcinoma (RCC), and researchers are now setting their sights on transforming upfront care, according to Chung-Han (Joe) Lee, MD

See more at:


Share This Post

Profile photo of Dena Battle
Dena Battle is the President of KCCure. She also serves on the Advisory Board for the Johns Hopkins Sidney Kimmel Cancer Center and as a member of the Patient and Family Advisory Council.

Lost Password


Subscribe for updates!